

05-01-01

PCT

JEC7 Rec'd PCT/PTO

30 APR 2001

BAKER BOTTS LLP

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

EXPRESS MAIL LABEL NO.

EF321689782US

DATE

April 30, 2001

ATTORNEY'S DOCKET NO.

32717-PCT-USA

U.S. APPLICATION NO.

Type assigned

09/830790

INTERNATIONAL APPLICATION NO.  
PCT/US00/26997INTERNATIONAL FILING DATE  
September 29, 2000PRIORITY DATE CLAIMED  
September 30, 1999

TITLE OF INVENTION A PROMOTIONAL IMPACT ASSESSMENT METHODOLOGY

APPLICANT(S) FOR DO/EO/US YUAN, Yilian

Applicant herewith submits to the United States Designated /Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210)
  - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409)
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ Other items or information:
  - a. ☒ a copy of the International Search Report (PCT/ISA/210)
  - b. ☐ a copy of the International Preliminary Examination Report (PCT/IPEA/409)

INTERNATIONAL FILING DATE <b>September 29, 2000</b>	PRIORITY DATE CLAIMED <b>September 30, 1999</b>	INTERNATIONAL FILING DATE <b>September 29, 2000</b>
17. <input checked="" type="checkbox"/> The following fees are submitted:		
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) Nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO (1.492(a)(3)) \$1,000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO (1.492(a)(5)) \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO (1.492(a)(2)) \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) (1.492(a)(1)) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfy provisions of PCT Article 33(1)-(4) \$100.00		
<b>ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 710</b>		
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)). \$		
<b>Claims</b>	<b>Number Filed</b>	<b>Number Extra</b>
<b>Rate</b>		
Total Claims	17 -20=	0
Independent Claims	1 -3=	0
Multiple dependent claim(s) (if applicable)		+ \$270.00
<b>TOTAL OF ABOVE CALCULATIONS = \$ 710</b>		
Reduction by 1/2 for filing by small entity, if applicable. \$		
<b>SUBTOTAL = \$ 710</b>		
Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)). \$		
<b>TOTAL NATIONAL FEE = \$ 710</b>		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$		
<b>TOTAL FEES ENCLOSED = \$ 710</b>		
Amt. refunded \$		
charged \$		
a. <input checked="" type="checkbox"/> A check in the amount of \$ 710 to cover the above fees is enclosed. b. [ ] Please charge our Deposit Account No. 02-4377 in amount of \$ to cover the above fees. A copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4377. A copy of this sheet is enclosed.		
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>		
SEND ALL CORRESPONDENCE TO: Paul A. Ragusa BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, New York 10112-4498		
Attorney: Paul A. Ragusa		
PTO Reg: 38,587		
April 30, 2001		
Date		

A PROMOTIONAL IMPACT ASSESSMENT METHODOLOGY

## SPECIFICATION

RELATED APPLICATION

5 The present application is based on U.S. provisional patent application serial number 60/157,139, filed September 30, 1999, from which priority is claimed.

## BACKGROUND OF THE INVENTION

1. Field of the Invention

10 The present invention is related to statistically measuring the impact of promotions on product sales, and more particularly, to techniques which employ time series analysis as part of an estimation methodology to determine such impact.

2. Related Art

15 Pharmaceutical companies spend billions of dollars each year to promote prescription drugs using various promotional vehicles. These include sales representatives detailing physicians about the information of their products and dropping free samples in doctors office, advertising in medical journals, continuing education programs for physician, and Direct-to-Consumer (DTC) advertising. With such financial and personnel investment, pharmaceutical companies need to measure the return on  
20 investment in prescription drug promotions. To do this, the impact of various promotions on product performance must be quantified.

Unfortunately, measuring the impact of promotions separately from other market inputs is not a simple task, as numerous factors may influence product performance. Moreover, it is well known that promotions have lagged effect, i.e.,  
25 adverting activities in this month may increase prescription volume or market share for the product in next month, and the effect may last for several months. To accurately estimate the promotional effects, this lag structure must be evaluated. This is a very complicated problem because many forms of promotions may happen at the same time

and each of them may have different lag structure. Furthermore, the promotion lag structures vary across products and across therapeutic classes. The fact that many market inputs other than promotions, such as price, product attributes, and the entry of competitive products, may impact product performance further complicates the detection of the promotional lag structure.

Time series analysis is one well-known econometric tool that has been applied to study the relationship between advertising and sales. G. E. P. Box and G. M. Jenkins in their book, "Time Series Analysis: Forecasting and Control," San Francisco: Holden-Day, Inc. (1976), laid down the theoretical foundation of time series analysis and Box-Jenkins transfer function analysis. R. M. Helmer and J. K. Johansson applied the Box-Jenkins transfer function analysis to studying the advertising-sales relationship using a vegetable compound data, see "An Exposition of the Box-Jenkins Transfer Function Analysis With an Application to the Advertising-Sales Relationship," *Journal of Marketing Research*, 227-239 (1977). In their article, the procedural steps in applying the transfer function analysis technique are specified and applied to the sample advertising-sales data with particular focus on the advertising lag structure.

In the article "The Impact of a Direct-to-Consumer Prescription Medication Advertising Campaign on New Prescription Volume," *Drug Information Journal*, Vol. 30, 715-729 (1996), L. R. Basara used the new prescription data of a newly launched prescription drug and the Direct-to-Consumer advertising data constructed a time-series regression model with lagged sales and a first-order moving-average residual. However, the methodologies in these articles failed to account for other market events and market inputs such as competitive product launches, additional indications approved, and product price. In the book W. H. Greene, "Econometric Analysis," Prentice-Hall, Inc. (1997), a comprehensive discussion of different functional forms of lagged effect is provided. The disclosures of the Box et. al., Helmer et al., Basara and Greene references are incorporated by reference herein.

While the use of time series analysis techniques in assessment of the impact of advertising on product sales is discussed in each of the forgoing articles and books, none of the prior articles' or books' techniques disclose a methodology for systematically assessing the impact of promotional activity on product performance while

taking into account other market variables. Accordingly, there exists a need in the art for a broad and accurate promotional impact assessment technique.

### SUMMARY OF THE INVENTION

An object of the present invention is to provide improved techniques for  
5 statistically measuring the impact of promotions on product sales.

A further object of the present invention is to provide improved techniques which employ time series analysis as part of an estimation methodology to determine the impact of promotions on product sales.

Yet another object of the present invention is to provide promotion  
10 response methodology for systematically assessing the impact of promotional activity on product performance while taking into account other market variables.

In order to achieve these objectives as well as others that will become apparent with reference to the following specification, the present invention provides techniques for estimating the impact of one or more promotions on product performance  
15 for a product are disclosed. In a preferred embodiment, a method is presented which involves determining market events which may impact product performance. The market events are examined to detect any abnormal event and, if abnormal events are detected, generating a description for each detected abnormal event. A relationship between each promotion and the product is then determined, and a promotion lag structure between the  
20 promotions and product performance is systematically detected. Functional forms are selected to account for any impact of the determined market events which may impact product performance, and are evaluated to account for the determined market event. The relationship between the promotions and product performance is quantified by taking into account the selected functional forms.

25 In one arrangement, the product is a pharmaceutical product, and the market event determining step involves manually determining one or more pharmaceutical market events which may impact pharmaceutical product performance. The abnormality examining step is then statistically determining whether any of the pharmaceutical market events is an abnormal event and, if one or more abnormal events  
30 are detected, generating statistical descriptions for each detected abnormal event.

In an especially preferred arrangement, the promotion lag detection step involves fitting a univariate auto-regressive model to each promotion to determine one or more promotion residual series, regressing performance information for the product to determine a product residual, transforming the product residual into a product residual series, determining one or more cross-correlation functions between the promotion residual series and product residual series, plotting the cross-correlation functions to detect any lagged effect from the promotions corresponding to those functions, and selecting appropriate functional form which best fit the plotted functions.

The accompanying drawings, which are incorporated and constitute part of this disclosure, illustrate a preferred embodiment of the invention and serve to explain the principles of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a functional diagram of a system in accordance with a preferred embodiment of the present invention;

Fig. 2 is a flow diagram illustrating the basic steps implemented in the system of Fig. 1;

Fig. 3 is a flow diagram illustrating the steps that may be implemented in one arrangement of a cross-correlation function useful in the system of Fig. 1; and

Fig. 4 is a flow diagram illustrating the steps that may be implemented in one arrangement of a functional form evaluation useful in the system of Fig. 1.

#### DESCRIPTION OF PREFERRED EMBODIMENTS

In general, the present invention adapts and expands upon certain time series analysis techniques so that the impact of any promotional activities on product performance can be determined. In particular, cross-correlation functions are used to systematically detect promotion lag structure, and different functional forms are used to account for other market inputs in the model. While as exemplary embodiment of the present invention will be described herein to estimate the number of new prescriptions of a product that are attributable to DTC advertising, the approach has general applicability to study the impact of other forms of promotions such as professional detailing, sampling,

and medical journal advertising, continuing medical educational events and meetings on product sales.

The present invention applies to studying the promotional impact on increasing both primary and secondary demand. To determine the impact on primary demand, the prescription volume for the therapeutic class is used as the outcome variable. To determine the impact on secondary demand, product market share is used as the outcome variable.

Referring to Fig. 1, one preferred arrangement of the present invention requires the execution of several logical steps, each of which are discussed below. All steps may be performed either manually or on a system 100 including a computer 110 executing standard off the shelf statistical software, such SAS® or EViews. It should be noted that the following description is by way of example and not by limitation, with certain embodiments being described in order to best explain the principles of the present invention.

Referring next to Fig. 2, the logical steps implemented in the preferred arrangement will be described with reference to the flow diagram 200. In step 210, the market events that may impact product performance, such as the arrival of new approved indications, the launch of competitive products, any positive or negative publicity, policy changes and the like, are identified. This step may be performed manually by a research analyst who is familiar with the particular market in the pharmaceutical industry.

In step 220, any abnormalities in the data collected by the research analyst are detected, and descriptive statistics for each variable under study are generated. For example, off the shelf statistical software may be used to check the data collected by the data analyst to determine whether an abnormal number of prescriptions occurred in a time period to flag a probable human error. The descriptive statistics, such as the mean, standard deviation, minimum and maximum quantities are calculated for each of the variables under study. This step is required to ensure the quality of the data.

In step 230, the model structure of multiplicative or additive which reflects the relationships between promotions and product prescription data to be multiplicative or additive is specified by the research analyst. The research analyst may repeat the analysis for both multiplicative and additive model structures and then select the better

model based on the modeling fitting information, the reasonableness of the coefficients estimates, and model robustness to changes in specification.

In step 240, a cross-correlation function is used to systematically detect promotion lag structure. Referring to Fig. 3, a highly preferred arrangement of step 240 is further discussed.

First, an univariate auto-regressive model is fit to the promotion data "X" in 310, as fully described in the Box et al. article. This fitting is performed to remove the trend and seasonal components from the promotion variable. The model structure and the coefficients will be used in later steps. The residual series is called XX.

Second, the prescription data Y is regressed on variables which are known to have impact on product performance 320, such as trend, new product launch, new indication approved, and the like, to determine the residual of Y. Any standard multiple regression algorithm may be used, such as PROC REG in SAS®. This regression is implemented to remove the impact of other market events on the prescription data.

Third, the model structure and coefficients estimated from the first sub-step are used 330 to transform the residual series of prescription data Y generated in 320 to determine a new residual series, YY.

Fourth, the cross- correlation function between the residual series XX determined in 310 and the residual series YY determined in 330 is calculated 340. The detailed definition of cross-covariance and cross-correlation is fully described in the Box and Jenkins book which provides that the estimation of cross - covariance of Y and X is:

$$C_{XY}(k) = \frac{1}{N} \sum_{t=1}^{N-k} (X_t - \bar{X})(Y_{t+k} - \bar{Y}) \quad k = \dots, -1, 0, 1, 2, \dots \quad (1)$$

where t is the time period, N is total number of time periods, k is number of time periods between X and Y,  $\bar{X}$  is the mean of X,  $\bar{Y}$  is the mean of Y. The estimation of cross - correlation of Y and X is:

$$r_{XY}(k) = C_{XY}(k) / S_X S_Y \quad k = \dots, -1, 0, 1, 2, \dots \quad (2)$$

where

$$S_X = \sqrt{C_{XX}(0)} \quad \text{and} \quad S_Y = \sqrt{C_{YY}(0)}$$



Fifth,  $r_{xy}(k)$  is plotted on one axis and  $k$  on the other axis to plot the cross correlation function 350, which is examined to detect the initial lag and the length of lagged effect. The time period when the cross correlation function starts to increase/decrease is the time period the promotional effect starts, i.e. the initial lag. The time period when the cross correlation function reduces to a low level indicates the time period the promotion effect disappeared, the difference between the time period of the initial lag and the time period when the effect disappeared is the length of the promotion lagged effect. This provides an initial assessment of the lag structure.

Finally, different functional forms, such as the Polynomial Distributed Lag, or the Geometric distributed lag as described in the WH Greene reference, are fit to the data 360. The functional form which best fits the data is chosen by comparing the models, as well as the sign and significance of the coefficients of the variables in the models.

Returning to Fig. 2, in step 250, appropriate functional forms to account for other market events, such as new product launch, new indications approved, positive/negative publicity, etc., are evaluated. Referring to Fig. 4, a highly preferred arrangement of step 250 is further discussed.

First, the prescription data is plotted against time to examine the temporal pattern of the data 410. The data may be plotted using prescription data as the vertical axis and time as the horizontal axis.

Second, based on the plotted data, a functional form is selected 420. At the time of the market event under consideration, such as a new product launch or new indication approval, or shortly after, if the prescription data exhibits shift in trend, marked by a changing slope:

$$M(t) = \begin{cases} 0, & t < T \\ t, & t \geq T \end{cases} \quad (3)$$

where  $T$  is the time of the market event, either  $M(t)$  is included as an independent variable in the model, or the interaction between  $M(t)$  and the trend variable is included as an independent variable in the model, with the model producing a smaller residual being selected.

Likewise, if the prescription data exhibits a jump, marked by a discontinuity:

$$0, t < T$$

$$M(t) = \begin{cases} 1, & t \geq T \end{cases} \quad (4)$$

either  $M(t)$  is included as an independent variable in the model, or the interaction

- 5 between  $M(t)$  and the trend variable is included as an independent variable in the model, with the model producing a smaller residual being selected.

- Finally, residual of the model and the coefficient estimate are examined  
430 to determine whether the  $T$  is correctly specified. Since some market input may have  
lagged effect, a small integer such as 1, 2 or 3 may need to be added to  $T$  to account for  
10 the lag. A big residual at time  $T$  indicates a problematic model fit. The pattern of the  
residual will suggest the choice of the  $T$ . For example, if there are big residuals for two  
time periods after  $T$ , the  $T$  should increase by two time periods.

- In step 260, the impact on prescription data of other variables such as  
product price, managed care impact, and the like, are evaluated, using the steps specified  
15 in step 240, by an analyst to determine whether the other variables are also impacting the  
prescription data and the lag structure.

In step 270, the multiplicative or additive models specified in step 230 are  
fit to quantify the relationship between prescription variables and promotion variables,  
and other market events and market inputs.

- 20 In step 280, multicollinearity problems between independent variables are  
checked. Some variables may have to be dropped due to the multicollinearity problem.

In step 290, the model residual is evaluated to detect any auto-correlation  
in residual. If there is auto-correlation in the residual, an autoregressive structure for the  
residual should be included in the model.

- 25 Finally, in step 295, the model is evaluated and validated to examine the  
stability and reasonableness of the model coefficients. For example, the model may be  
tested using the next several months of data to validate the model. The model estimates  
of the variables are applied to the next several months of data to compute sales, and are  
compared actual sales.

- 30 As described above, one advantage of the present invention is to combine  
econometric modeling techniques with transfer function analysis techniques in time series

analysis to detect the lag structure, and to quantify the effects of various promotions controlling for the impact of other factors. Using time series data of promotions and other key market inputs, this methodology can isolate and quantify promotional effects on products' prescription share and the total therapeutic class prescription volume. This methodology is applicable to measuring a wide range of promotional effects including DTC, professional detailing, sampling, and medical journal spending, and continuing medical educational events and meetings while controlling factors known to influence market share such as prescription price, competitive product launch, new indication approved, positive/negative publicity etc. Without accounting for the impact of these factors appropriately, it would not be possible to accurately measure the incremental prescriptions attributable to promotions.

Previous work done by Helmer and Johansson, and Basara applied the transfer function analysis to studying the promotional lagged effect, but failed to account for other market events and market inputs such as new product launches, new indications approved, positive/negative publicity, product price. As stated previously, this may result in inaccurate estimates of the promotional effects. Others accounted for some of the market inputs but relied on past experience and a "trail and error" approach to detect the promotional lag structure. The "trail and error" approach is time consuming and past experience may result in biased estimates because past experience may not be applicable to new promotional vehicles.

The foregoing merely illustrates the principles of the invention. Various modifications and alterations to the described embodiments will be apparent to those skilled in the art in view of the teachings herein. For example, this methodology may be modified to analyze the sales and promotions and other market inputs for consumer packaged goods. It will thus be appreciated that those skilled in the art will be able to devise numerous systems and methods which, although not explicitly shown or described herein, embody the principles of the invention and are thus within the spirit and scope of the invention.

CLAIMS

1. A method for estimating the impact of one or more promotions on product performance for a product, comprising the steps of:

- a. determining one or more market events which may impact said product performance;
- b. examining said determined one or more market events to detect any abnormal event and, if one or more abnormal events are detected; generating a description for each detected abnormal event;
- c. determining a relationship between each of said one or more promotions and said product;
- d. systematically detecting a promotion lag structure between said one or more promotions and said product performance for said product;
- e. selecting one or more functional forms to account for any impact of each of said one or more determined market events which may impact said product performance;
- f. evaluating each of said selected functional forms to account for said one or more determined market events, and
- g. quantifying a relationship between said one or more promotions and said product performance for said product by taking into account said evaluated selected functional forms.

2. The method of claim 1, further comprising the step of checking for any multicollinearity problems between said one or more promotions, said product performance, and said evaluated selected functional forms.

3. The method of claim 2, wherein said relationship between said one or more promotions and said product performance includes a quantified portion and a residual portion, and further comprising the step of evaluating said residual portion to detect auto-correlation.

4. The method of claim 3, further comprising the step of evaluating and validating said quantified relationship.

5. The method of claim 1, wherein said product is a pharmaceutical product, and said market event determining step comprises manually determining one or more pharmaceutical market events which may impact said pharmaceutical product performance.

6. The method of claim 5, wherein said abnormality examining step comprises statistically determining whether any of said one or more pharmaceutical market events is an abnormal event and, if one or more abnormal events are detected; generating statistical descriptions for each detected abnormal event.

7. The method of claim 6, wherein said relationship determining step comprises determining a relationship between each of said one or more promotions and said product to be a relationship selected from the group consisting of multiplicative, additive, or other.

8. The method of claim 1, wherein said promotion lag detection step comprises:

- (a) fitting a univariate auto-regressive model to each of said one or more promotions to determine one or more promotion residual series;
- (b) regressing performance information for said product to determine a product residual;
- (c) transforming said product residual into a product residual series;
- (d) determining one or more cross- correlation functions between said one or more promotion residual series and said product residual series;
- (e) plotting said one or more cross- correlation functions to detect any lagged effect from said one or more promotions corresponding to said one or more cross- correlation functions; and

(f) selecting one or more appropriate functional form which best fits said plotted functions.

9. The method of claim 1, wherein said functional form selection step comprises:

5 (a) plotting pharmaceutical product sales verses time to determine any temporal relationship; and

(b) selecting said functional form by examining said plotted data.

10. The method of claim 1, wherein said functional form evaluation step comprises graphical evaluation.

11. A system for estimating the impact of one or more predetermined promotions on product performance for a product by taking into account one or more predetermined market events which may impact said product performance, comprising:

15 a. means for examining said predetermined one or more market events to detect any abnormal event and for generating a description for each detected abnormal event, if any;

b. means for determining a relationship between each of said one or more predetermined promotions and said product;

20 c. means, responsive to said abnormality descriptions generated by said abnormality examining means and said determined relationships from said relationship determining means, for systematically detecting a promotion lag structure between said one or more promotions and said product performance for said product based on said abnormality descriptions and said determined relationships;

25 d. means, responsive to said predetermined market events, for selecting one or more functional forms to account for any impact of each of said one or more predetermined market events which may impact said product performance;

e. means, responsive to said selected functional forms generated by

said selection means, for evaluating each of said selected functional forms to account for said one or more determined market events, and

f. means, responsive to said detected promotion lag structure and evaluated selected functional forms, for quantifying a relationship between said one or more promotions and said product performance for said product by taking into account said promotion lag structure and evaluated selected functional forms.

12. The system of claim 11, further comprising means, responsive to said quantified relationships, for checking for any multicollinearity problems between said one or more promotions, said product performance, and said evaluated selected functional forms.

13. The system of claim 11, wherein said relationship between said one or more promotions and said product performance includes a quantified portion and a residual portion, and further comprising means, responsive to said quantified relationships, for evaluating said residual portion to detect auto-correlation.

14. The system of claim 11, further comprising means, responsive to said quantified relationships, for evaluating and validating said quantified relationship.

15. The system of claim 11, wherein said product is a pharmaceutical product, and said abnormality examining means includes means for statistically determining whether any of said one or more pharmaceutical market events is an abnormal event.

16. The system of claim 11, wherein said promotion lag detection means further includes:

(a) means for fitting a univariate auto-regressive model to each of said one or more promotions to determine one or more promotion residual series;

(b) means for regressing performance information for said product to determine a product residual;

(c) means, responsive to said product residual determined by said regressing performance means, for transforming said product residual into a

product residual series;

(d) means, responsive to said product residual series transformed by said transforming means and to said promotion residual series determined by said fitting means, for determining one or more cross- correlation functions between said one or more promotion residual series and said product residual series;

(e) means, responsive to said one or more cross- correlation functions determined by said cross-correlation function determining means, for plotting said one or more cross- correlation functions to detect any lagged effect from said one or more promotions corresponding to said one or more cross- correlation functions; and

(f) means, responsive to said plotting means, for selecting one or more appropriate functional form which best fits said plotted functions.

17. The system of claim 11, wherein said functional form selection means includes:

(a) means for plotting pharmaceutical product sales verses time to determine any temporal relationship; and

(b) means, responsive to said plotting means, for selecting said functional form by examining said plotted data.



ABSTRACT

Techniques for estimating the impact of one or more promotions on product performance for a product are disclosed. In a preferred embodiment, a method is presented which involves determining market events which may impact product performance. The market events are examined to detect any abnormal event and, if abnormal events are detected, generating a description for each detected abnormal event. A relationship between each promotion and the product is then determined, and a promotion lag structure between the promotions and product performance is systematically detected. Functional forms are selected to account for any impact of the determined market events which may impact product performance, and are evaluated to account for the determined market event. The relationship between the promotions and product performance is quantified by taking into account the selected functional forms.

1/4

100




FIG. 1

110

2/4




FIG.2

3/4





FIG.3





## COMBINED DECLARATION AND POWER OF ATTORNEY

(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

### A PROMOTIONAL IMPACT ASSESSMENT METHODOLOGY

This declaration is of the following type:

- ☐ original
- ☐ design
- ☒ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

the specification of which: *(complete (a), (b), or (c))*

(a) ☐ is attached hereto.

(b) ☒ [X] was filed on April 30, 2001 as Application Serial No. 09/830,790 and was amended on *(if applicable)*.

(c) ☒ [X] was described and claimed in PCT International Application No. PCT/US00/26997 filed on September 29, 2000 and was amended on *(if applicable)*.

### Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

[ ] In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

### Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

*(complete (d) or (e))*

(d) ☐ no such applications have been filed.

(e) ☐ such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION				
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION				
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
				<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>

### Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date
60/157,139	September 30, 1999

### Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

*(complete this part only if this is a divisional, continuation or C-I-P application)*

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

### Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439; Rochelle K. Seide Reg. No. 32,300; Gary M. Butter, Reg. No. 33,841; Marta E. Delsignore, Reg. No. 32,689; and Lisa B. Kole, Reg. No. 35,225 of the firm of BAKER BOTTS L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO:  
BAKER BOTTS L.L.P.  
30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112  
CUSTOMER NUMBER: 21003

DIRECT TELEPHONE CALLS TO:  
BAKER BOTTS L.L.P.  
(212) 705-5000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both,

under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME Yuan	FIRST NAME Yilian	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY North Wales	STATE or FOREIGN COUNTRY Pennsylvania PA	COUNTRY OF CITIZENSHIP United States	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 129 Tudor Drive	CITY North Wales	STATE or COUNTRY Pennsylvania	ZIP CODE 19454
DATE 6/27/2001	SIGNATURE OF INVENTOR <i>Yilian Yuan, Ph.D.</i>			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			

Check proper box(es) for any added page(s) forming a part of this declaration

- [ ] Signature for ninth and subsequent joint inventors. Number of pages added \_\_\_\_\_.
- [ ] Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor.  
Number of pages added \_\_\_\_\_.
- [ ] Signature for inventor who refuses to sign, or cannot be reached, by person authorized under 37 CFR 1.47.  
Number of pages added \_\_\_\_\_.